191 related articles for article (PubMed ID: 25870069)
21. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
22. Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers.
DeVane CL; Markowitz JS; Carson SW; Boulton DW; Gill HS; Nahas Z; Risch SC
J Clin Psychopharmacol; 2000 Jun; 20(3):347-9. PubMed ID: 10831022
[TBL] [Abstract][Full Text] [Related]
23. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects.
Charles BG; Miller AK; Nasveld PE; Reid MG; Harris IE; Edstein MD
Antimicrob Agents Chemother; 2007 Aug; 51(8):2709-15. PubMed ID: 17517850
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
26. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
27. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
28. Tafenoquine: the new kid on the block.
Chen V; Daily JP
Curr Opin Infect Dis; 2019 Oct; 32(5):407-412. PubMed ID: 31305490
[TBL] [Abstract][Full Text] [Related]
29. The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg).
Dow G; Smith B
Malar J; 2017 May; 16(1):209. PubMed ID: 28526056
[TBL] [Abstract][Full Text] [Related]
30. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
Preskorn SH
J Psychiatr Pract; 2010 Jan; 16(1):46-9. PubMed ID: 20098230
[TBL] [Abstract][Full Text] [Related]
31. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.
Bogni A; Monshouwer M; Moscone A; Hidestrand M; Ingelman-Sundberg M; Hartung T; Coecke S
Toxicol In Vitro; 2005 Aug; 19(5):621-9. PubMed ID: 15893449
[TBL] [Abstract][Full Text] [Related]
32. Measurements of 5,6-Orthoquinone, a Surrogate for the Presumed Active Primaquine Metabolite 5-Hydroxyprimaquine, in the Urine of Cambodian Adults.
Vanachayangkul P; Sea D; Wojnarski M; Sok S; Kodchakorn C; Ta-Aksorn W; Hom S; Ittiverakul M; Kuntawunginn W; Arsanok M; Buathong N; Heng TK; Nareth K; Nou S; Chandara S; Ly S; Oung P; Vesely B; Bennett J; Reichard G; Pybus B; Lanteri C; Saunders D; Fukuda M; Smith P; Dysoley L; Rekol H; Waters NC; Spring M
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0182121. PubMed ID: 34978892
[TBL] [Abstract][Full Text] [Related]
33. Tafenoquine: A Step toward Malaria Elimination.
Lu KY; Derbyshire ER
Biochemistry; 2020 Mar; 59(8):911-920. PubMed ID: 32073254
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
Elmes NJ; Nasveld PE; Kitchener SJ; Kocisko DA; Edstein MD
Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1095-101. PubMed ID: 18541280
[TBL] [Abstract][Full Text] [Related]
35. Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.
Kitchener S; Nasveld P; Edstein MD
Am J Trop Med Hyg; 2007 Mar; 76(3):494-6. PubMed ID: 17360873
[TBL] [Abstract][Full Text] [Related]
36. Causal prophylactic efficacy of primaquine, tafenoquine, and atovaquone-proguanil against Plasmodium cynomolgi in a rhesus monkey model.
DiTusa C; Kozar MP; Pybus B; Sousa J; Berman J; Gettayacamin M; Im-erbsin R; Tungtaeng A; Ohrt C
J Parasitol; 2014 Oct; 100(5):671-3. PubMed ID: 24780070
[TBL] [Abstract][Full Text] [Related]
37. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine.
Pybus BS; Sousa JC; Jin X; Ferguson JA; Christian RE; Barnhart R; Vuong C; Sciotti RJ; Reichard GA; Kozar MP; Walker LA; Ohrt C; Melendez V
Malar J; 2012 Aug; 11():259. PubMed ID: 22856549
[TBL] [Abstract][Full Text] [Related]
38. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
40. Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in thai soldiers receiving monthly prophylaxis.
Edstein MD; Kocisko DA; Walsh DS; Eamsila C; Charles BG; Rieckmann KH
Clin Infect Dis; 2003 Dec; 37(12):1654-8. PubMed ID: 14689348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
